🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 655.83 +0.1% NASDAQ 100: 584.98 +0.1% Dow Jones: 465.06 -0.1%

Paradigm Biocapital Advisors - Q3 2025 13F Filings

PA

Paradigm Biocapital Advisors Lp

CIK: 0001855655
Address: New York New York 767 Third Avenue, 17Th Floor
$3.52 B
Portfolio Value
36
Assets Held
Reporting Period: Q3 2025
Filing Status:
Active
Last Updated: 02/17/2026

Portfolio Summary (Q3 2025)

View Full Portfolio Analysis

Top Buys

Q3 2025
1. ABVX Abivax Société Anonyme
+$132.8 M
2. GMAB Genmab A/S
+$117.06 M
3. CDTX Cidara Therapeutics
+$92.04 M
4. URGN Urogen Pharma
+$84.11 M
5. AGIO Agios Pharmaceuticals
+$61.46 M

Top Sells

Q3 2025
1. COGT Cogent Biosciences
−$103.34 M
2. ONC Beone Medicines
−$84.19 M
3. IRON Disc Medicine
−$63.65 M
4. MLTX Moonlake Immunotherapeutics
−$41.46 M
5. LENZ Lenz Therapeutics
−$29.98 M

Asset Allocation

Stocks/ETFs
+44.30%
$3.38 B 96.12%
Options
+100.00%
$136.47 M 3.88%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Paradigm Biocapital Advisors Q3 2025 Filing Summary

Paradigm Biocapital Advisors Lp filed its 13F report for Q3 2025 on November 14, 2025. The portfolio totaled 3.52 B reflecting a +50.13% change from the prior quarter, spanning 36 assets. The top 10 holdings comprised 68.0% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 10 new positions and 5 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Paradigm Biocapital Advisors’s Q3 2025 Filing

Paradigm Biocapital Advisors submitted their Form 13F-HR for the Q3 2025 period on 11/14/2025. This was the only submission for the quarter.

In the Q3 2025 filing, Paradigm Biocapital Advisors reported a managed portfolio value of 3.52 B, consisting of 36 individual positions.

This page displays the raw filing documents. To see which stocks Paradigm Biocapital Advisors bought or sold during Q3 2025, please visit Paradigm Biocapital Advisors's Portfolio Analysis page.